Tagged with BI

Pharma Legal Handbook Please describe the main cost containment policies in place in your country and their fundamental principles   a. Pricing and impact of generic/biosimilar approval The SFDA applies automatic price reductions for generics and biosimilars: The 1st generic is priced ≥35% lower than the originator. The 2nd generic is ≥55% lower.…

France As CEO of Transgene, Alessandro Riva is steering the French biotech into a new era of cancer immunotherapy. Building on more than four decades of scientific excellence, Transgene is advancing a pioneering platform of individualised neoantigen therapeutic vaccines (INTVs) designed to re-educate the immune system to target solid tumours. With…

France Under Laurence Rodriguez’s leadership, GenSight Biologics is charting a bold path forward after a period of reset, advancing groundbreaking gene therapies for rare ophthalmic and mitochondrial diseases. She reflects on rebuilding the organisation, preparing a pivotal Phase III study for the gene therapy GS010/LUMEVOQ, and shaping the future of optogenetic…

France Born from a serendipitous scientific discovery in Montpellier, Abivax has evolved into one of France’s most promising global biotechs. Led by CEO Marc de Garidel, the company is harnessing its pioneering miR-124-based therapy, obefazimod, to redefine treatment possibilities in inflammatory bowel disease through an entirely new, immune-balancing mechanism of action.…

France Genopole stands as one of France’s leading bioclusters, seamlessly integrating world-class research, entrepreneurship, and industrial engagement to support over 80 companies across health and the bioeconomy. Under Gilles Trystram’s leadership, the cluster nurtures innovation from start-up creation to scaling, leveraging strategic partnerships with institutions like Université Paris-Saclay and specialised platforms…

Colombia Francisco Rossi, Director of Colombia’s National Food and Drug Surveillance Institute (INVIMA), discusses the agency’s ongoing transformation to become a faster, more transparent, and globally recognised regulator. Since his return in 2024, Rossi has prioritised reducing backlogs, launching the digital platform InvimÁgil, and refocusing INVIMA on public health surveillance. He…

France Pascal Houdayer, recently appointed CEO and the first non-family investor of Boiron, brings three decades of global leadership experience to one of France’s most iconic healthcare enterprises. In this conversation, he reflects on Boiron’s evolution from a pioneer in homeopathy to a global advocate of integrative health, its diversification into…

China In just four years, Shanghai-based Argo Biopharma has gone from a start-up to one of China’s most internationally recognised RNA innovators and has signed two major licensing deals with Novartis worth up to USD 6 billion. These Novartis deals could come to be one of the largest ever tie-ups between…

Switzerland With over seven decades of innovation behind it, Lupin has evolved from an Indian pioneer in anti-tuberculosis therapies into a global pharmaceutical leader shaping the future of complex generics, speciality care, and biosimilars. As the company accelerates its European expansion, Laurent Renaudie shares how Lupin’s entrepreneurial culture, patient-centred mission, and…

USA As the world’s largest stock exchange, the New York Stock Exchange (NYSE) plays a pivotal role in shaping access to capital for healthcare and life sciences companies. Johanna Grossman, PhD, who leads this sector for the NYSE, reflects on her career path, the exchange’s growing footprint in biotech, and the…

USA Tim Scott, President and CEO of Biocom California, leads the state’s largest and most influential life sciences association at a pivotal moment for the industry. With more than 1,800 members across biotech, pharma, medtech, diagnostics, and research institutions, Biocom California represents the full breadth of the ecosystem. In this interview,…

USA In 2025, just 318 US biotech deals closed in Q2 – the lowest in a decade – even as mega-rounds propped up total investment volumes. For a sector that was booming during the pandemic era, the contrast could not be starker. Leaders from trade organisations and innovation accelerators agree on…